dMed, A Collaborative Shanghai CRO Consulting Startup, Lands $8 Million

dMed Company Limited, a Shanghai CRO specialist founded in August, closed an $8 million first-round financing. Qiming Venture Capital was the lead investor joined by Tairui Investment, ZAI Laboratory and others. ZAI has enlisted dMed as an advisor for China clinical trials of its PARP program. dMed was founded by Dr. Lingshi Tan, who also set up Pfizer's China R&D center. After 20 years at Pfizer, Dr. Tan said he wanted to work on a larger scale to aid China drug development. It would be a shame, he said, if a China innovative drug development program failed because the clinical trials were poorly structured or carelessly carried out.